An Improved Receptor-Based Pharmacophore Generation Algorithm Guided by Atomic Chemical Characteristics and Hybridization Types

Overview

Journal Front Pharmacol

Date 2019 Jan 9

PMID 30618755

Citations 6

Authors

Gaoqi He

Bojie Gong

Jianqiang Li

Yiping Song

Shiliang Li

Xingjian Lu

Affiliations

Soon will be listed here.

Abstract

Pharmacophore-based virtual screening is an important and leading compound discovery method. However, current pharmacophore generation algorithms suffer from difficulties, such as ligand-dependent computation and massive extractive chemical features. On the basis of the features extracted by the five probes in Pocket v.3, this paper presents an improved receptor-based pharmacophore generation algorithm guided by atomic chemical characteristics and hybridization types. The algorithm works under the constraint of receptor atom hybridization types and space distance. Four chemical characteristics (H-A, H-D, and positive and negative charges) were extracted using the hybridization type of receptor atoms, and the feature point sets were merged with 3 Å space constraints. Furthermore, on the basis of the original extraction of hydrophobic characteristics, extraction of aromatic ring chemical characteristics was achieved by counting the number of aromatics, searching for residual base aromatic ring, and determining the direction of aromatic rings. Accordingly, extraction of six kinds of chemical characteristics of the pharmacophore was achieved. In view of the pharmacophore characteristics, our algorithm was compared with the existing LigandScout algorithm. The results demonstrate that the pharmacophore possessing six chemical characteristics can be characterized using our algorithm, which features fewer pharmacophore characteristics and is ligand independent. The computation of many instances from the directory of useful decoy dataset show that the active molecules and decoy molecules can be effectively differentiated through the presented method in this paper.

Citing Articles

Structure-activity relationship of pharmacophores and toxicophores: the need for clinical strategy.

Saganuwan S Daru. 2024; 32(2):781-800.

PMID: 38935265 PMC: 11555194. DOI: 10.1007/s40199-024-00525-y.

: A Versatile Workflow for the Generation of Receptor-based Pharmacophore Models for Virtual Screening.

Heider J, Kilian J, Garifulina A, Hering S, Langer T, Seidel T J Chem Inf Model. 2022; 63(1):101-110.

PMID: 36526584 PMC: 9832483. DOI: 10.1021/acs.jcim.2c00814.

Pharmacophore-Model-Based Virtual-Screening Approaches Identified Novel Natural Molecular Candidates for Treating Human Neuroblastoma.

Dain Md Opo F, Alkarim S, Alrefaei G, Molla M, Alsubhi N, Alzahrani F Curr Issues Mol Biol. 2022; 44(10):4838-4858.

PMID: 36286044 PMC: 9600652. DOI: 10.3390/cimb44100329.

Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein.

Opo F, Rahman M, Ahammad F, Ahmed I, Bhuiyan M, Asiri A Sci Rep. 2021; 11(1):4049.

PMID: 33603068 PMC: 7892887. DOI: 10.1038/s41598-021-83626-x.

G protein-coupled receptors: structure- and function-based drug discovery.

Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y Signal Transduct Target Ther. 2021; 6(1):7.

PMID: 33414387 PMC: 7790836. DOI: 10.1038/s41392-020-00435-w.

References

Hoffren A, Murray C, Hoffmann R . Structure-based focusing using pharmacophores derived from the active site of 17beta-hydroxysteroid dehydrogenase. Curr Pharm Des. 2001; 7(7):547-66. DOI: 10.2174/1381612013397870. View

Carlson H . Protein flexibility is an important component of structure-based drug discovery. Curr Pharm Des. 2002; 8(17):1571-8. DOI: 10.2174/1381612023394232. View

Carlson H . Protein flexibility and drug design: how to hit a moving target. Curr Opin Chem Biol. 2002; 6(4):447-52. DOI: 10.1016/s1367-5931(02)00341-1. View

Schmitt S, Kuhn D, Klebe G . A new method to detect related function among proteins independent of sequence and fold homology. J Mol Biol. 2002; 323(2):387-406. DOI: 10.1016/s0022-2836(02)00811-2. View

Guner O . History and evolution of the pharmacophore concept in computer-aided drug design. Curr Top Med Chem. 2002; 2(12):1321-32. DOI: 10.2174/1568026023392940. View

Bohm H . LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J Comput Aided Mol Des. 1992; 6(6):593-606. DOI: 10.1007/BF00126217. View

Erickson J, Jalaie M, Robertson D, Lewis R, Vieth M . Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J Med Chem. 2003; 47(1):45-55. DOI: 10.1021/jm030209y. View

Rauh D, Klebe G, Stubbs M . Understanding protein-ligand interactions: the price of protein flexibility. J Mol Biol. 2004; 335(5):1325-41. DOI: 10.1016/j.jmb.2003.11.041. View

Dror O, Shulman-Peleg A, Nussinov R, Wolfson H . Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr Med Chem. 2004; 11(1):71-90. DOI: 10.2174/0929867043456287. View

10.

Wolber G, Langer T . LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005; 45(1):160-9. DOI: 10.1021/ci049885e. View

11.

Bohm H . The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des. 1992; 6(1):61-78. DOI: 10.1007/BF00124387. View

12.

Chen J, Lai L . Pocket v.2: further developments on receptor-based pharmacophore modeling. J Chem Inf Model. 2006; 46(6):2684-91. DOI: 10.1021/ci600246s. View

13.

Huang N, Shoichet B, Irwin J . Benchmarking sets for molecular docking. J Med Chem. 2006; 49(23):6789-801. PMC: 3383317. DOI: 10.1021/jm0608356. View

14.

Yuan Y, Pei J, Lai L . LigBuilder 2: a practical de novo drug design approach. J Chem Inf Model. 2011; 51(5):1083-91. DOI: 10.1021/ci100350u. View

15.

Chen C . A novel integrated framework and improved methodology of computer-aided drug design. Curr Top Med Chem. 2013; 13(9):965-88. DOI: 10.2174/1568026611313090002. View

16.

Chen J, Ma X, Yuan Y, Pei J, Lai L . Protein-protein interface analysis and hot spots identification for chemical ligand design. Curr Pharm Des. 2013; 20(8):1192-200. DOI: 10.2174/13816128113199990065. View

17.

Boobbyer D, Goodford P, McWhinnie P, Wade R . New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J Med Chem. 1989; 32(5):1083-94. DOI: 10.1021/jm00125a025. View

18.

Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X . PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017; 45(W1):W356-W360. PMC: 5793840. DOI: 10.1093/nar/gkx374. View

19.

Machaba K, Mhlongo N, Dokurugu Y, Soliman M . Tailored-pharmacophore model to enhance virtual screening and drug discovery: a case study on the identification of potential inhibitors against drug-resistant Mycobacterium tuberculosis (3R)-hydroxyacyl-ACP dehydratases. Future Med Chem. 2017; 9(10):1055-1071. DOI: 10.4155/fmc-2017-0020. View

20.

Xu Y, Wang S, Hu Q, Gao S, Ma X, Zhang W . CavityPlus: a web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction. Nucleic Acids Res. 2018; 46(W1):W374-W379. PMC: 6031032. DOI: 10.1093/nar/gky380. View